288 related articles for article (PubMed ID: 38270784)
1. Cancer-associated thrombosis in hematologic malignancies.
Fukatsu M; Ikezoe T
Int J Hematol; 2024 May; 119(5):516-525. PubMed ID: 38270784
[TBL] [Abstract][Full Text] [Related]
2. Incidence and pathogenesis of thrombosis in hematologic malignancies.
Kwaan HC; Vicuna B
Semin Thromb Hemost; 2007 Jun; 33(4):303-12. PubMed ID: 17525887
[TBL] [Abstract][Full Text] [Related]
3. Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.
Falanga A; Rickles FR
Hematology Am Soc Hematol Educ Program; 2007; ():165-71. PubMed ID: 18024625
[TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis and treatment of hematological malignancy-associated thrombosis].
Ikezoe T
Rinsho Ketsueki; 2023; 64(9):1137-1143. PubMed ID: 37899193
[TBL] [Abstract][Full Text] [Related]
5. Hematologic malignancies and thrombosis.
Elice F; Rodeghiero F
Thromb Res; 2012 Mar; 129(3):360-6. PubMed ID: 22197450
[TBL] [Abstract][Full Text] [Related]
6. Intravascular clotting activation and bleeding in patients with hematologic malignancies.
Tallman MS; Kwaan HC
Rev Clin Exp Hematol; 2004 Jun; 8(1):E1. PubMed ID: 16029967
[TBL] [Abstract][Full Text] [Related]
7. Management of thrombosis in patients with hematologic malignancies.
Piccioli A; Vianello F; Prandoni P
Curr Hematol Rep; 2002 Sep; 1(1):79-83. PubMed ID: 12901128
[TBL] [Abstract][Full Text] [Related]
8. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis in hematological malignancies: mechanisms and implications.
Horowitz NA; Brenner B
Thromb Res; 2020 Jul; 191 Suppl 1():S58-S62. PubMed ID: 32736780
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis and hemostatic abnormalities in hematological malignancies.
Colombo R; Gallipoli P; Castelli R
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):441-50. PubMed ID: 25018062
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism incidence in hematologic malignancies.
Kekre N; Connors JM
Blood Rev; 2019 Jan; 33():24-32. PubMed ID: 30262170
[TBL] [Abstract][Full Text] [Related]
12. Bleeding complications in patients with hematologic malignancies.
Franchini M; Frattini F; Crestani S; Bonfanti C
Semin Thromb Hemost; 2013 Feb; 39(1):94-100. PubMed ID: 23247655
[TBL] [Abstract][Full Text] [Related]
13. Disseminated intravascular coagulation in hematologic malignancies.
Franchini M; Di Minno MN; Coppola A
Semin Thromb Hemost; 2010 Jun; 36(4):388-403. PubMed ID: 20614391
[TBL] [Abstract][Full Text] [Related]
14. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Verma D; Kantarjian H; Strom SS; Rios MB; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; O'Brien S; Cortes J
Blood; 2011 Oct; 118(16):4353-8. PubMed ID: 21846902
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis.
Hsu C; Patell R; Zwicker JI
Blood Adv; 2023 Sep; 7(17):4721-4727. PubMed ID: 36170802
[TBL] [Abstract][Full Text] [Related]
16. Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders.
Alipanahzadeh H; Ghulamreza R; Shokouhian M; Bagheri M; Maleknia M
J Thromb Thrombolysis; 2020 Aug; 50(2):318-329. PubMed ID: 31808122
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy of early use of recombinant soluble thrombomodulin for disseminated intravascular coagulation complicated with hematologic malignancies].
Usami M; Kuroda H; Yoshida M; Sakamoto H; Shimoyama S; Kanari Y; Yamada M; Abe T; Fujii S; Maeda M
Rinsho Ketsueki; 2015 Jun; 56(6):673-80. PubMed ID: 26256878
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic complications in malignant haematological disorders.
Castelli R; Ferrari B; Cortelezzi A; Guariglia A
Curr Vasc Pharmacol; 2010 Jul; 8(4):482-94. PubMed ID: 19485900
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis in children with hematologic malignancies.
Schobess R; Kempf-Bielack B; Schwabe D; Sträter R; Nowak-Göttl U
Rev Clin Exp Hematol; 2004 Jun; 8(1):E2. PubMed ID: 16029968
[TBL] [Abstract][Full Text] [Related]
20. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J; de la Cruz J; Cedillo Á; Llamas P; Duarte R; Jiménez-Yuste V; Hernández-Rivas JÁ; Gil-Manso R; Kwon M; Sánchez-Godoy P; Martínez-Barranco P; Colás-Lahuerta B; Herrera P; Benito-Parra L; Alegre A; Velasco A; Matilla A; Aláez-Usón MC; Martos-Martínez R; Martínez-Chamorro C; Susana-Quiroz K; Del Campo JF; de la Fuente A; Herráez R; Pascual A; Gómez E; Pérez-Oteyza J; Ruiz E; Alonso A; González-Medina J; Martín-Buitrago LN; Canales M; González-Gascón I; Vicente-Ayuso MC; Valenciano S; Roa MG; Monteliu PE; López-Jiménez J; Escobar CE; Ortiz-Martín J; Diez-Martin JL; Martinez-Lopez J;
J Hematol Oncol; 2020 Oct; 13(1):133. PubMed ID: 33032660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
